| Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine F Krammer, K Srivastava, H Alshammary, AA Amoako, MH Awawda, ... New England Journal of Medicine 384 (14), 1372-1374, 2021 | 807 | 2021 |
| Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron JM Carreño, H Alshammary, J Tcheou, G Singh, A Raskin, H Kawabata, ... Nature, 1-8, 2021 | 451 | 2021 |
| SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 F Amanat, M Thapa, T Lei, SMS Ahmed, DC Adelsberg, JM Carreño, ... Cell 184 (15), 3936-3948. e10, 2021 | 248 | 2021 |
| A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial R Nachbagauer, J Feser, A Naficy, DI Bernstein, J Guptill, EB Walter, ... Nature Medicine 27 (1), 106-114, 2021 | 248 | 2021 |
| Defining the risk of SARS-CoV-2 variants on immune protection MM DeGrace, E Ghedin, MB Frieman, F Krammer, A Grifoni, A Alisoltani, ... Nature, 1-17, 2022 | 136 | 2022 |
| SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals K Sano, D Bhavsar, G Singh, D Floda, K Srivastava, C Gleason, ... Nature communications 13 (1), 1-8, 2022 | 80 | 2022 |
| Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains B Ying, B Whitener, LA VanBlargan, AO Hassan, S Shrihari, CY Liang, ... bioRxiv, 2021 | 67 | 2021 |
| Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines Y Ju, JM Carreño, V Simon, K Dawson, F Krammer, SJ Kent Nature Reviews Immunology, 1-2, 2022 | 56 | 2022 |
| mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations JM Carreño, G Singh, J Tcheou, K Srivastava, C Gleason, H Muramatsu, ... medRxiv, 2022 | 42 | 2022 |
| Reduced antibody activity against SARS-CoV-2 B. 1.617. 2 Delta virus in serum of mRNA-vaccinated patients receiving TNF-alpha inhibitors RE Chen, MJ Gorman, DY Zhu, JM Carreno, D Yuan, LA VanBlargan, ... medRxiv, 2021 | 40* | 2021 |
| The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD F Amanat, M Thapa, T Lei, SMS Ahmed, DC Adelsberg, JM Carreno, ... medRxiv, 2021 | 40 | 2021 |
| Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients JM Carreño, H Alshammary, G Singh, A Raskin, F Amanat, A Amoako, ... EBioMedicine 73, 103626, 2021 | 39 | 2021 |
| Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses N Pardi, JM Carreño, G O’Dell, J Tan, C Bajusz, H Muramatsu, W Rijnink, ... Nature communications 13 (1), 1-14, 2022 | 36 | 2022 |
| Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs JH Lara-Puente, JM Carreño, W Sun, A Suárez-Martínez, ... Mbio 12 (5), e01908-21, 2021 | 35 | 2021 |
| Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase … BL Innis, LD Mercer, JA White, R Scharf, R Hjorth, S Lamola, ... medRxiv, 2021 | 35* | 2021 |
| Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses M McMahon, G O’Dell, J Tan, A Sárközy, M Vadovics, JM Carreño, ... Proceedings of the National Academy of Sciences 119 (45), e2206333119, 2022 | 34 | 2022 |
| Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study A Ozonoff, J Schaenman, ND Jayavelu, CE Milliren, CS Calfee, CB Cairns, ... EBioMedicine 83, 104208, 2022 | 33 | 2022 |
| Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR M Schwarz, D Torre, D Lozano-Ojalvo, AT Tan, T Tabaglio, S Mzoughi, ... Nature biotechnology 40 (11), 1680-1689, 2022 | 29 | 2022 |
| Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants AS Gonzalez-Reiche, H Alshammary, S Schaefer, G Patel, J Polanco, ... Nature Communications 14 (1), 3235, 2023 | 27 | 2023 |
| Bivalent COVID-19 booster vaccines and the absence of BA. 5-specific antibodies JM Carreño, G Singh, V Simon, F Krammer The Lancet Microbe, 2023 | 25 | 2023 |
